Biofrontera Inc. (BFRI)

NASDAQ: BFRI · USD

$0.87

+0.03 (+3.6%)· Recorded snapshot

Market cap	12.9M
Revenue (ttm)	46.2M
Net income (ttm)	-6.4M
EPS (ttm)	-$0.54
Shares out	14.9M
P/E (forward)	5.4x
Volume	138,791
Beta	0.88

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 46.2M
Net income (ttm): -6.4M
EPS (ttm): -$0.54
P/E (forward): 5.4x
Market cap: 12.9M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Conserver

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E5.4

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-988.4

P25 n/aP50 n/aP75 n/a

ROIC-55.9

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All BFRI indicators

Market & fundamental data

Available fields

209

Groups with data

Currency

USD

Showing 209 of 209 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001858685
Company name	Biofrontera Inc.
Country	United States
Country code	US
CUSIP number	09077D209
Earnings date	2026-11-11
Earnings time	amc
Employees	94
Employees change	1
Employees growth	1.08%
Enterprise value	$15.8M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1997
Industry	Drug Manufacturers - Specialty & Generic
IPO date	2021-10-29
Is primary listing	Yes
Is SPAC	No
ISIN number	US09077D2099
Last 10-K release date	2026-03-19
Last earnings date	2026-08-13
Last refreshed	2026-10-28
Last stock split date	2023-07-05
Last stock split type	Reverse
Market cap	$12.9M
Market cap category	Nano-Cap
Next earnings date	2026-11-11
Options	No
Price	$0.87
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	BFRI
U.S. state	Massachusetts
Website	https://www.biofrontera-us.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-62.15%
EV/Sales	0.34x
FCF / EV yield	-50.8%
FCF yield	-62.08%
Forward EV/Sales	0.34x
Forward P/E	5.44x
Forward P/S	0.28x
Industry forward P/E	13.87x
Industry P/E	173.94x
P/B ratio	2x
P/S ratio	0.28x
Price / tangible book value	3.77x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-13.36%
EBITDA margin	-12.92%
Gross margin	79.25%
Operating margin	-13.36%
Pretax margin	-13.72%
Profit margin	-13.78%
Profit per employee	$-67,713
Revenue per employee	$491,223
ROA	-17.45%
ROA (5Y)	-30.86%
ROCE	-45.63%
ROE	-988.35%
ROE (5Y)	-221.95%
ROIC	-55.91%
SBC / revenue	2.45%
Tax / revenue	0.06%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	4
EPS growth years	2
Gross profit growth	58.21%
Gross profit growth (Q)	50.17%
Gross profit growth 3Y	37.49%
Gross profit growth 5Y	26.48%
Net income growth quarters	1
Net income growth years	2
Revenue growth	17.83%
Revenue growth (Q)	32.92%
Revenue growth (QoQ)	19.03%
Revenue growth 3Y	16.71%
Revenue growth 5Y	15.54%
Revenue growth quarters	3
Revenue growth years	5

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-3,000
Depreciation and amortization	$203,000
EBIT	$-6.2M
EBITDA	$-6M
EPS	$-0.54
FCF per share	$-0.53
Financing cash flow	$2.4M
Free cash flow	$-7.9M
Free cash flow minus SBC	$-9.1M
Gross profit	$36.6M
Income taxes	$29,000
Investing cash flow	$3M
Net cash flow	$-2.6M
Net income	$-6.4M
Operating cash flow minus SBC	$-9.1M
Operating income	$-6.2M
Revenue	$46.2M
Stock-based compensation	$1.1M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-6.24
Book value per share	$0.42
Debt / equity	1.26
Interest coverage	-12.78
Long-term assets	$11.6M
Long-term liabilities	$7.6M
Net cash (debt)	$-2.8M
Net cash / market cap	-22.21%
Net debt / equity	0.48
Piotroski F-Score	3
Property, plant and equipment	$5M
Shareholders' equity	$6M
Tangible book value	$3.4M
Tangible book value per share	$0.24
Total assets	$24.1M
Total cash	$4.7M
Total debt	$7.5M
Total liabilities	$18.1M
WACC	7.59%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	2.09
Current assets	$12.4M
Current liabilities	$10.5M
Current ratio	1.18
Inventory turnover	3.74
Net working capital	$-2.3M
Quick ratio	1
Working capital	$1.9M
Working capital turnover	90.36

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-49.16%
Dividend yield	0%
Shareholder yield	-49.16%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$1.09
1D price change	3.6%
1M price change	-26.84%
1M total return	-26.84%
1W price change	7.38%
1W total return	7.38%
1Y price change	-15.78%
1Y return CAGR	-15.79%
1Y total return	-15.78%
20-day SMA	$0.88
200-day SMA	$1.03
3M price change	-17.78%
3M total return	-17.78%
3Y price change	-76.35%
3Y return CAGR	-38.15%
3Y total return	-76.35%
50-day SMA	$1.18
50-day SMA vs 200-day SMA	50over200
52-week high	$1.66
52-week high date	2026-09-08
52-week low	$0.55
52-week low date	2025-12-31
6M price change	-23.6%
6M total return	-23.6%
All-time high	$292.60
All-time high date	2021-12-21
All-time low	$0.54
All-time low date	2025-05-30
Average true range (ATR)	$0.07
Average volume	240.8K
Beta (1Y)	2.22
Beta (2Y)	1.02
Beta (5Y)	0.88
Change from 52-week high	-47.59%
Change from 52-week low	56.84%
Change from all-time high	-99.7%
Change from all-time low	61.06%
Change from open	1.16%
Day's gap	2.41%
Dollar volume	$120,748
High price	$0.87
Low price	$0.86
Monthly RSI	34.85
Open price	$0.86
Position in 52-week range	100%
Premarket change	1.67%
Premarket close	$0.84
Premarket price	$0.85
Previous close	$0.84
Price vs 150-day SMA	-20.51%
Price vs 20-day SMA	-1.47%
Price vs 200-day SMA	-16.43%
Price vs 50-day SMA	-26.59%
Relative volume	0.58
Return from IPO open	-98.95%
Return from IPO price	-82.8%
RSI	39.61
Sharpe ratio	0.14
Sharpe ratio (3Y)	0.01
Sortino ratio	0.28
Sortino ratio (3Y)	0.08
Volume	138.8K
Weekly RSI	40.78
YTD price change	51.46%
YTD total return	51.46%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	11.8M
Float percentage	79.56%
Shares change (QoQ)	10.62%
Shares change (YoY)	49.16%
Shares held by insiders	9.16%
Shares held by institutions	12.4%
Shares outstanding	14.9M
Short % of float	1.24%
Short % of shares	0.99%
Short ratio	0.2 days

Deeper analysis on BFRI

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this BFRI report

Is a complete BFRI research report available?

No complete published report is available for Biofrontera Inc. (BFRI) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Biofrontera Inc. (BFRI)

Price

Financial snapshot

Fair-value bridge

Latest news · BFRI

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All BFRI indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on BFRI

Frequently asked questions